Indonesia has opened its first botulinum toxin manufacturing facility, with production scheduled to begin in 2028. The plant represents a significant shift in toxin supply-chain geography, moving production outside traditional hubs in South Korea, China, and the United States. Local production capacity could lower regional costs and reduce import tariffs across Southeast Asia and the broader Indo-Pacific market.